Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus (AREBAG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03510624
Recruitment Status : Recruiting
First Posted : April 27, 2018
Last Update Posted : November 11, 2019
Sponsor:
Information provided by (Responsible Party):
Universitaire Ziekenhuizen Leuven

Brief Summary:
Investigate the acute effect of the steviol glycoside, rebaudioside A, on the glucose excursion during an oral glucose tolerance test in 30 patients with type 2 diabetes mellitus.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Drug: Rebaudioside A Drug: Placebo Phase 1

Detailed Description:
Eligible individuals with type 2 diabetes mellitus will be invited for four study visits. During the first and third study visit, rebaudioside A or the placebo will be administered. During the second and fourth study visit, an oral glucose tolerance test (OGTT) will be executed to measure the response of administration of rebaudioside A versus placebo on the glucose homeostasis. The area under the curve blood glucose values during the first two hours of the OGTT will be compared for both conditions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Investigation of the Acute Effect of Rebaudioside A on the Glucose Excursion During an Oral Glucose Tolerance Test in 30 Patients With Type 2 Diabetes Mellitus (AREBAG)
Actual Study Start Date : November 9, 2018
Estimated Primary Completion Date : July 1, 2020
Estimated Study Completion Date : July 1, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: First rebaudioside A and then placebo Drug: Rebaudioside A
Rebaudioside A 3g

Drug: Placebo
Empty capsules

Experimental: First placebo and then rebaudioside A Drug: Rebaudioside A
Rebaudioside A 3g

Drug: Placebo
Empty capsules




Primary Outcome Measures :
  1. Area under the curve (AUC) blood glucose concentrations during an OGTT [ Time Frame: 0 to 2 hours after glucose challenge ]
    Area under the curve blood glucose concentrations during an OGTT


Secondary Outcome Measures :
  1. AUC glucose/insulin/glucagon [ Time Frame: -30 to 0 min of OGTT ]
    AUC glucose/insulin/glucagon

  2. AUC glucose/insulin/glucagon [ Time Frame: 0 to 30 min of OGTT ]
    AUC glucose/insulin/glucagon

  3. AUC glucose/insulin/glucagon [ Time Frame: 0 to 4 hours of OGTT ]
    AUC glucose/insulin/glucagon

  4. Maximal blood glucose [ Time Frame: -30 min to 4 hours of OGTT ]
    Maximal blood glucose

  5. Maximal blood glucose excursion [ Time Frame: -30 min to 4 hours of OGTT ]
    Maximal blood glucose excursion

  6. Maximal serum insulin [ Time Frame: -30 min to 4 hours of OGTT ]
    Maximal serum insulin

  7. Maximal serum glucagon [ Time Frame: -30 min to 4 hours of OGTT ]
    Maximal serum glucagon

  8. Concentration(t) (C(t))rebaudioside A, steviol and steviol glucuronide [ Time Frame: -30 min to 4 hours of OGTT ]
    Concentration of rebaudioside A, steviol and steviol glucuronide on different time points



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed and dated written informed consent
  • Understand procedures
  • Type 2 diabetes mellitus
  • Body Mass Index (BMI): 25 - 40 kg/m2
  • HbA1c: 6.5-8%
  • Judged to be in good health

Exclusion Criteria:

  • Subject is unable to

    • Refrain from stevia leaves, stevia extracts or steviol glycoside-containing products from 5 days prior to administration of rebaudioside A or placebo until discharge from the unit after the OGTT on the consecutive day.
    • Refrain from quinine-containing products from 72h prior to administration of rebaudioside A or placebo until discharge from the unit after the OGTT on the consecutive day.
    • Maintain their habitual diets and physical activity patterns and refrain from engaging in strenuous physical activities from 72h prior to administration of rebaudioside A or placebo until discharge from the unit after the OGTT on the consecutive day.
    • Refrain from grapefruit products from 14 days before study visit 1 until discharge from the unit after the OGTT on study visit 4.
    • Refrain from alcohol from 24h prior to administration of rebaudioside A or placebo until discharge from the unit after the OGTT on the consecutive day.
    • Refrain from caffeine containing products from 12h prior to administration of rebaudioside A or placebo until discharge from the unit after the OGTT on the consecutive day.
    • Fast at least 5 hours prior to the administration of rebaudioside A or placebo on study days 1 and 3.
    • Fast at least 10 hours prior to the study days 2 and 4.
  • Women of childbearing potential (last menstruation less than 1 year prior to screening) who are pregnant, lactating or planning to become pregnant during the study.
  • Individuals with other forms of diabetes
  • Current or previous treatment with any diabetes drug within 3 months prior to screening, except for metformin.
  • Symptomatic hyperglycemia requiring immediate therapy during screening, in the judgement of the principal investigator.
  • Evidence of significant diabetic complications.
  • History of pancreas or beta-cell transplantation.
  • Presence or history of clinically relevant medical, surgical or psychiatric conditions likely to affect the subject's safety in this trial or that could confound the study assessments or endpoints.
  • Clinically relevant abnormal physical findings.
  • Clinically significant abnormalities of vital signs:

    • Seated systolic blood pressure outside 90-160 mmHg
    • Diastolic blood pressure outside 40-100 mmHg
    • Heart rate <50 bpm
    • Corrected QT (QTC) using Fridericia's formulae >450 msec (for men) or >470 msec (for women) measured with a 12-lead electrocardiogram.
    • Clinically significant abnormal laboratory values.
    • Moderate or severe renal dysfunction defined as a calculated glomerular filtration rate (GFR) <30 ml/min.
  • Currently active or history of alcohol abuse.
  • Currently active or history of drug addiction or currently a regular user of drugs including "recreational use" of any illicit drug.
  • Smoking cigarettes or using nicotine-containing products, during the last 6 months prior to screening, as nicotine inhibits the Transient Receptor Potential 5 (TRPM5) channel.
  • Individuals for whom a major surgery is planned to occur between screening and the end of the trial.
  • Previous or current use of concomitant medication, which would confound the study conduct or implicate a risk for safety of the participant, as judged by the investigator(s).
  • History of relevant drug or food allergies or a history of severe anaphylactic reaction.
  • History of hypersensitivity to the study drug or any of the excipients or to medicinal products with similar chemical structures.
  • Individuals with hepatitis B and/or hepatitis C virus.
  • Individuals with Human Immunodeficiency Virus (HIV).
  • Participation in another clinical trial involving an investigational product within the 3 months preceding screening or 5-halflives of the drug studied, whichever is longer, prior to study supplement administration. Or, participation in any other type of medical research within 3 months preceding screening judged not to be scientifically or medically compatible with this study.
  • Individuals who have donated or lost more than 500 ml blood or plasma within 3 months prior to screening.
  • Individuals unable to swallow orally administered medication.
  • Individuals in which catheter placement is impossible (amputation, no visible veins, …)
  • Individuals that cannot speak or understand the Dutch language.
  • In the opinion of the principal investigator any other factor that could interfere with the subject's ability to provide informed consent or to complete the study with strict compliance to the study protocol, or that could hold safety concerns for the subject or could impact the outcome of the study results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03510624


Contacts
Layout table for location contacts
Contact: Caroline Simoens, MD +3216345268 caroline.simoens@kuleuven.be
Contact: Bart Van der Schueren, PhD +32340822 bart.vanderschueren@uzleuven.be

Locations
Layout table for location information
Belgium
Centrum Clinical Pharmacology Recruiting
Leuven, Flanders, Belgium, 3000
Contact: Caroline Simoens    +3216345268    caroline.simoens@kuleuven.be   
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
Investigators
Layout table for investigator information
Principal Investigator: Bart Van der Schueren UZ Leuven

Layout table for additonal information
Responsible Party: Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier: NCT03510624     History of Changes
Other Study ID Numbers: s61580
First Posted: April 27, 2018    Key Record Dates
Last Update Posted: November 11, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases